Solvotrin Therapeutics: Funding, Investors & Team (Sep 2026)
Solvotrin Therapeutics Limited is a privately held pharmaceutical company focused on cardiovascular applications. Solvotrin’s business model is based on the development of new drugs that combine its unique patented prodrug platform with well established compounds in large markets. Its approach of chemically creating new chemical entities from existing compounds for synergistic benefits creates efficacy and safety advantages with significantly reduced development timeline and development risk. Solvotrin’s lead compound, ST0702 is a nicotinic acid prodrug, with significant efficacy and tolerability advantages over similar products for 54 dyslipidaemia. ST0701 is a bioactivated form of aspirin, which addresses the well documented gastrointestinal toxicity of aspirin. ST0703 is a ’nitro-aspirin‘ prodrug with dual antiplatelet effects and disease modifying potential. The company has a strong intellectual property underpin with patent protection at the highest, New Molecule level. Solvotrin’s strategy is to take its compounds to the end of Phase I and to partner the development and commercialisation phases with large pharmaceutical companies.
Solvotrin Therapeutics has raised $6.7M across 1 funding round on record, the most recent an undisclosed round of $6.7M announced in Nov 2020.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Solvotrin Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2020.
Solvotrin Therapeutics Funding Rounds
Solvotrin Therapeutics Founders and Leadership Team
Contact details for the Solvotrin Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Solvotrin Therapeutics Funding Compared to Other Health Care Startups
Solvotrin Therapeutics' latest round of $6.7M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Solvotrin Therapeutics in Health Care and Cork
Companies Similar to Solvotrin Therapeutics
NeuroBell are developing a novel medical device providing portable EEG monitoring with real-time &automated…
Vertigenius designs and deploys customized exercises using an easy-to-use clinician portal and even uses a…
CrannMed aims to eliminate chronic pain, restore mobility, and stop disease progression for patients with…
Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal…
It has been estimated that up to 25% of people with diabetes will develop a foot ulcer at some point in their…
Rockfield Medical Devices is an innovative SME in the area of human centered design process in the medical…
The Tight Alright technology developed by FeelTect is a connected-health device designed to measure and…
ProVerum Medical is a healthcare company that creates new therapies for benign prostatic hyperplasia (BPH).…
CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with…
When a patient is critically ill, giving their doctor the right information at the right time can mean the…
SISU is a collection of doctor-led, patient-centric aesthetic medical clinics.
Vida Care offers patients the opportunity to easily schedule various routine tests such as blood,…
Solvotrin Therapeutics Funding FAQs
What does Solvotrin Therapeutics do?
Solvotrin Therapeutics Limited is a privately held pharmaceutical company focused on cardiovascular applications. Solvotrin’s business model is based on the development of new drugs that combine its unique patented prodrug platform with well established compounds in large markets. Its approach of chemically creating new chemical entities from existing compounds for synergistic benefits creates efficacy and safety advantages with significantly reduced development timeline and development risk. Solvotrin’s lead compound, ST0702 is a nicotinic acid prodrug, with significant efficacy and tolerability advantages over similar products for 54 dyslipidaemia. ST0701 is a bioactivated form of aspirin, which addresses the well documented gastrointestinal toxicity of aspirin. ST0703 is a ’nitro-aspirin‘ prodrug with dual antiplatelet effects and disease modifying potential. The company has a strong intellectual property underpin with patent protection at the highest, New Molecule level. Solvotrin’s strategy is to take its compounds to the end of Phase I and to partner the development and commercialisation phases with large pharmaceutical companies.
How much funding has Solvotrin Therapeutics raised?
Solvotrin Therapeutics has raised $6.7M across 1 round on record. The most recent is an undisclosed round of $6.7M announced in Nov 2020.
When did Solvotrin Therapeutics last raise funding?
Solvotrin Therapeutics' most recent funding round on record is an undisclosed round of $6.7M, announced in Nov 2020.
Who is the CEO of Solvotrin Therapeutics?
Pat O'Flynn is listed as CEO at Solvotrin Therapeutics.
Where is Solvotrin Therapeutics headquartered?
Solvotrin Therapeutics is based in Cork, Ireland.
How many employees does Solvotrin Therapeutics have?
Solvotrin Therapeutics is in the 11-50 employee band.
How does Solvotrin Therapeutics' funding compare to other Health Care startups?
Solvotrin Therapeutics' latest round of $6.7M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Solvotrin Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Solvotrin Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.